adverse events;clinical changes;clinical changes;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;medically attended adverse events (MAAEs);New Onset Chronic Medical Condition (NOCMCs);Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;serious adverse events (SAEs);solicited injection site or systemic reactions;unsolicited adverse events;vital signs;vital signs

adverse events;clinical changes;clinical changes;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean of the fold-rise post-vaccination of psVNT-50 neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;Geometric mean titers of neutralizing antibody titer;medically attended adverse events (MAAEs);New Onset Chronic Medical Condition (NOCMCs);Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;Proportion of participants with at least 4-fold-rise in neutralizing antibody titer;serious adverse events (SAEs);solicited injection site or systemic reactions;unsolicited adverse events;vital signs;vital signs